Skip to content
  • Facebook
  • Twitter
This translation is automatically provided by Google; please refer to the original English version for appropriate wording.
Take on Typhoid

Take on Typhoid

  • Home
  • Why Typhoid?
    • Typhoid & Related Salmonelloses
    • Global Research
    • Links & Resources
  • The Issues
    • Vaccines
    • WASH
    • Drug-Resistant Typhoid
    • Treatment
    • Diagnostics
    • Typhoid intestinal perforation
    • Related Issues
  • Resources & Tools
    • Talk About Typhoid
    • Global Policy
    • Country Tools
    • Infographics
    • Fact Sheets
    • TCV Cost-effectiveness
    • Share on Social
  • Blog & News
    • Blog
    • News
    • Publications
    • Newsletter
  • International Conference
    • Past Conferences
    • Conference Travel
  • About Us
    • About the Coalition against Typhoid
    • About the Typhoid Vaccine Acceleration Consortium

TCV is highly immunogenic in Malawian children

Posted on September 15, 2021 by Laura Kallen

New results from an immune response study in Malawi found that TCV may offer longer-lasting protection of up to three years for children as young as 9 months old!

learn more

Post navigation

Now we know: typhoid conjugate vaccines are highly effective in African children
Take on Typhoid Newsletter September 2021

Related Posts

  • ‘Death Is Part of Our Daily Lives’: Yarmouk Typhoid Outbreak Spreads

  • Introducing the New Coalition against Typhoid Website

  • ​ Knowledge Exchange Newsletter, December 2016

  • One step closer to untreatable typhoid

Newsletter Signup

Recent Posts

  • Pakistan prioritizes typhoid control with expanded surveillance efforts

  • Kenya’s milestone campaign to protect more than 20 million children from typhoid

  • In an uncertain world, TCVs provide protection

  • A mother’s battle

  • মায়ের যুদ্ধ

cat
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Coalition against Typhoid
2000 Pennsylvania Ave, NW, Suite 7000
Washington, DC 20006
© 2018. Coalition Against Typhoid. All Rights Reserved.
  • Contact Us
  • Privacy Policy
  • Facebook
  • Twitter
Top